We report a T cell lymphoma (TCL) occurring 3 months after anti-CD19 chimeric antigen
receptor (CAR) T cell immunotherapy for non-Hodgkin B cell lymphoma. The TCL was …

Unanswered questions following reports of secondary malignancies after CAR-T cell therapy |
Nature Medicine Skip to main content Thank you for visiting nature.com. You are using a browser …

Chimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment of several
haematological malignancies and is being investigated in patients with various solid …

Background The risk of second tumors after chimeric antigen receptor (CAR) T-cell therapy,
especially the risk of T-cell neoplasms related to viral vector integration, is an emerging …

Despite recent advances in frontline therapy for diffuse large B-cell lymphoma (DLBCL), at
least a third of those diagnosed still will require second or further lines for relapsed or …

Adoptive T cell therapies have produced exceptional responses in a subset of patients with
cancer. However, therapeutic efficacy can be hindered by poor T cell persistence and …

COI notes: Competing interests: RB reports consulting: BMS, Caribou Biosciences,
Genentech, Janssen, Pfizer, Sanofi, SparkCures; Research: Novartis, Pack Health. CP …

The introduction of chimeric antigen receptor (CAR) T-cell therapy represents a landmark
advancement in treating resistant forms of cancer such as leukemia, lymphoma, and …

COI notes: NNS receives research funding from Lentigen, VOR Bio, and CARGO
Therapeutics. NNS has attended advisory board meetings (no honoraria) for VOR …

PURPOSE Compare the association of individual comorbidities, comorbidity indices, and
survival in older adults with non-Hodgkin lymphoma (NHL), including in specific NHL …